What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
Ryerson Holding (NYSE: RYI) finalises Olympic Steel acquisition as North American metals consolidation accelerates
Read More 5 minute read Pharma Industry News What makes Aptar Pharma’s latest nasal drug delivery bet a potential market disruptor? Aptar Pharma teams up with Dianosic to advance a bioresorbable nasal scaffold platform for chronic sinus and rhinitis care. Find out how this could reshape treatment. byPallavi MadhirajuSeptember 6, 2025